Plain-English translation of NCT06567470 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called CIT-013 to see if it can help reduce the signs and symptoms of rheumatoid arthritis. Researchers want to understand how well this treatment works and whether it is safe for patients to use. You would receive either the medication or a placebo (a dummy injection) over the course of 12 weeks.
Current treatments for rheumatoid arthritis don't work well enough for everyone, and some patients need better options to control their joint inflammation and pain. This trial is exploring whether this new treatment could offer patients another way to manage their condition.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic once every 2 weeks for a total of 12 weeks. During each visit, you would receive an injection of either CIT-013 or placebo, and the research team would check how you're doing with blood tests and physical exams. You would also monitor your symptoms at home and report back on how you're feeling between visits.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Belgium
Germany